Rath R N, Das B K, Ali M L, Das P K, Mishra A C, Mohapatra B N
Department of Medicine, S.C.B. Medical College.
Indian J Med Res. 1990 Jul;91:277-81.
Centperazine, an analogue of DEC, was subjected to a double blind controlled trial, to evaluate its efficacy as a newer antifilarial agent. Centperazine (300 mg/day) along with equivalent quantities of DEC and placebo were administered to different types of filariasis patients. DEC was found to be significantly effective in reducing peripheral microfilaraemia, in different weeks and months of follow-up, except at the end of 6th month, as compared to Centperazine. There was no significant difference between the placebo and Centperazine treated patients, in this respect, revealing that the drugs had no efficacy in eliminating peripheral microfilaraemia. Recurrence of acute attack within 6 months was nearly equal with both Centperazine and DEC, being 28.2 and 24 per cent respectively, whereas in the placebo group the recurrence rate was 48.9 per cent. Centperazine treated patients showed significantly less side effects (8.9%), as compared to DEC treated patients (34%). Giddiness, nausea and vomiting were the common adverse effects observed.
乙胺嗪的类似物哌嗪被用于一项双盲对照试验，以评估其作为一种新型抗丝虫药的疗效。将哌嗪（300毫克/天）与等量的乙胺嗪和安慰剂给予不同类型的丝虫病患者。与哌嗪相比，发现乙胺嗪在随访的不同周和月中，除了在第6个月末外，在降低外周血微丝蚴血症方面有显著效果。在这方面，安慰剂治疗组和哌嗪治疗组患者之间没有显著差异，表明这些药物在消除外周血微丝蚴血症方面没有疗效。6个月内急性发作的复发率在哌嗪组和乙胺嗪组中几乎相同，分别为28.2%和24%，而在安慰剂组中复发率为48.9%。与乙胺嗪治疗组患者（34%）相比，哌嗪治疗组患者的副作用明显更少（8.9%）。头晕、恶心和呕吐是观察到的常见不良反应。
